The Shanghai Municipal Medical Products Administration has disclosed that Hengshan (H&S) Pharmaceutical is under scrutiny for the alleged manufacture of substandard medications. The company faces not only the seizure of the non-compliant drugs but also a financial penalty. H&S Pharmaceutical has been charged RMB 295,753.58 for the illicit proceeds derived from these activities and slapped with a substantial fine totaling RMB 6,283,515.6.
On July 5, 2022, an inspection was conducted on a batch of diclofenac sustained-release capsules (I) produced by Hengshan Pharma, a unit of H&S Pharmaceutical. The specific product in question was identified with the specification of 0.1g, batch number 220306, and packaged in a format of 12 tablets per plate, with one plate per box. Following rigorous examination by the Shanghai Institute of Food and Drug Control and subsequent retesting by the China National Institutes for Food and Drug Control, it was determined that the “release” aspect of the “inspection” criteria for this batch of drugs failed to meet the stipulations of the national drug standard WS1-(X-080)-2006Z-2011, as documented in the reports YC202201600 and HF202208950.- Flcube.com
